Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
Stock Snapshot
Novo Nordisk(NVO) stock is priced at $50.34, giving the company a market capitalization of 229.84B. It carries a P/E multiple of 14.63 and pays a dividend yield of 2.4%.
As of 2025-12-13, Novo Nordisk(NVO) stock has fluctuated between $49.81 and $50.84. The current price stands at $50.34, placing the stock +1.1% above today's low and -1.0% off the high.
Novo Nordisk(NVO) shares are trading with a volume of 12.39M, against a daily average of 13.89M.
In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $109.88 and a 52-week low of $43.08.
In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $109.88 and a 52-week low of $43.08.
NVO News
Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor m...
On Friday, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Novo Nordisk A/S’ (NYSE:NVO...
Danish drugmaker Novo Nordisk (NVO) launched its blockbuster diabetes treatment Ozempic (semaglutide injection) in India at an entry price of $24.35 per week (2...
Analyst ratings
55%
of 33 ratingsMore NVO News
The company states: “Today, the European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, issued a positive opinion for a higher dose of...
Regulators at the U.S. Food and Drug Administration (FDA) are reportedly weighing whether to sharply accelerate early-stage review steps for Eli Lilly and Co.’s...
Image source: The Motley Fool. Nov. 5, 2025 at 12:00 a.m. ET Call participants President & Chief Executive Officer — Maziar Doustdar Executive Vice President,...
Shares of Wave Life Sciences WVE have soared 183% in the past week after the company reported encouraging interim data from an early-stage study evaluating its...
Novo Nordisk A/S shares have fallen so much this year that it’s almost as if the frenzy around weight-loss drugs that propelled the Danish pharmaceutical compan...
The obesity treatment space has been generating plenty of headlines – and sales – over the past few years. GLP-1 receptor agonists such as semaglutide (Wegovy)...
Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next. Usually, Wall Stre...
